International Journal of Infection

Published by: Kowsar

Sofosbuvir and Ribavirin to Treat Hepatitis C Virus Genotype 4 Infection in a 65-Year-Old Patient With Diabetes and Low Platelet: A Case Report

Nawfal R Hussein 1 , *
Author Information
1 Department of Internal Medicine, College of Medicine, University of Duhok, Duhok, Iraq
Article information
  • International Journal of Infection: October 01, 2016, 3 (4); e36642
  • Published Online: August 3, 2016
  • Article Type: Case Report
  • Received: January 25, 2016
  • Revised: January 27, 2016
  • Accepted: January 28, 2016
  • DOI: 10.17795/iji-36642

To Cite: Hussein N R. Sofosbuvir and Ribavirin to Treat Hepatitis C Virus Genotype 4 Infection in a 65-Year-Old Patient With Diabetes and Low Platelet: A Case Report, Int J Infect. 2016 ; 3(4):e36642. doi: 10.17795/iji-36642.

Copyright © 2016, Infectious Diseases and Tropical Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Case Presentation
3. Discussion
  • 1. Hussein NR. Prevalence of HBV, HCV and HIV and Anti-HBs antibodies positivity in healthcare workers in departments of surgery in Duhok City, Kurdistan Region, Iraq. Int J Pure Appl Sci Technol. 2015; 26(2): 70
  • 2. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis. 2012; 55 Suppl 1-5[DOI][PubMed]
  • 3. Koshy A, Madda JP, Marcellin P, Martinot M. Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone. J Clin Gastroenterol. 2002; 35(1): 82-5[PubMed]
  • 4. Legrand-Abravanel F, Colson P, Leguillou-Guillemette H, Alric L, Ravaux I, Lunel-Fabiani F, et al. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J Med Virol. 2009; 81(12): 2029-35[DOI][PubMed]
  • 5. Hussein NR, Tunjel I, Basharat Z, Taha A, Irving W. The treatment of HCV in patients with haemoglobinopathy in Kurdistan Region, Iraq: a single centre experience. Epidemiol Infect. 2016; 144(8): 1634-40[DOI][PubMed]
  • 6. Vespasiani-Gentilucci U, Galati G, Gallo P, De Vincentis A, Riva E, Picardi A. Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens. World J Gastroenterol. 2015; 21(24): 7412-26[DOI][PubMed]
  • 7. Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014; 21(11): 762-8[DOI][PubMed]
  • 8. Aronsohn A, Ancuta I, Caruntu F, Coppola C, Delic D, Digiacomo A, et al. Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort. J Viral Hepat. 2014; 21(5): 377-80[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments